These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 12925455)

  • 21. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial.
    Ibanez B; Macaya C; Sánchez-Brunete V; Pizarro G; Fernández-Friera L; Mateos A; Fernández-Ortiz A; García-Ruiz JM; García-Álvarez A; Iñiguez A; Jiménez-Borreguero J; López-Romero P; Fernández-Jiménez R; Goicolea J; Ruiz-Mateos B; Bastante T; Arias M; Iglesias-Vázquez JA; Rodriguez MD; Escalera N; Acebal C; Cabrera JA; Valenciano J; Pérez de Prado A; Fernández-Campos MJ; Casado I; García-Rubira JC; García-Prieto J; Sanz-Rosa D; Cuellas C; Hernández-Antolín R; Albarrán A; Fernández-Vázquez F; de la Torre-Hernández JM; Pocock S; Sanz G; Fuster V
    Circulation; 2013 Oct; 128(14):1495-503. PubMed ID: 24002794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pexelizumab -- a C5 complement inhibitor for use in both acute myocardial infarction and cardiac surgery with cardiopulmonary bypass.
    Fleisig AJ; Verrier ED
    Expert Opin Biol Ther; 2005 Jun; 5(6):833-9. PubMed ID: 15952913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pexelizumab, an Anti-C5 Complement Antibody for Primary Coronary Revascularization: A New Insight from Old Versions.
    Lin GM
    Cardiovasc Hematol Disord Drug Targets; 2011; 11(2):97-101. PubMed ID: 22044037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
    Buller CE; Fu Y; Mahaffey KW; Todaro TG; Adams P; Westerhout CM; White HD; van 't Hof AW; Van de Werf FJ; Wagner GS; Granger CB; Armstrong PW
    Circulation; 2008 Sep; 118(13):1335-46. PubMed ID: 18779444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial.
    Lincoff AM; Roe M; Aylward P; Galla J; Rynkiewicz A; Guetta V; Zelizko M; Kleiman N; White H; McErlean E; Erlinge D; Laine M; Dos Santos Ferreira JM; Goodman S; Mehta S; Atar D; Suryapranata H; Jensen SE; Forster T; Fernandez-Ortiz A; Schoors D; Radke P; Belli G; Brennan D; Bell G; Krucoff M;
    Eur Heart J; 2014 Oct; 35(37):2516-23. PubMed ID: 24796339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study.
    Deftereos S; Giannopoulos G; Angelidis C; Alexopoulos N; Filippatos G; Papoutsidakis N; Sianos G; Goudevenos J; Alexopoulos D; Pyrgakis V; Cleman MW; Manolis AS; Tousoulis D; Lekakis J
    Circulation; 2015 Oct; 132(15):1395-403. PubMed ID: 26265659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Trendelenburg M; Theroux P; Stebbins A; Granger C; Armstrong P; Pfisterer M
    Eur Heart J; 2010 May; 31(10):1181-7. PubMed ID: 20089518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of iron chelation on myocardial infarct size and oxidative stress in ST-elevation-myocardial infarction.
    Chan W; Taylor AJ; Ellims AH; Lefkovits L; Wong C; Kingwell BA; Natoli A; Croft KD; Mori T; Kaye DM; Dart AM; Duffy SJ
    Circ Cardiovasc Interv; 2012 Apr; 5(2):270-8. PubMed ID: 22496085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy.
    Ezekowitz JA; Armstrong PW; Granger CB; Theroux P; Stebbins A; Kim RJ; Patel MR
    Am Heart J; 2010 Aug; 160(2):272-8. PubMed ID: 20691832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The safety and efficacy of systemic salvage thrombolysis in acute myocardial infarct].
    Sarullo FM; Schicchi R; Schirò M; Americo L; Bonnì G; Faraone N; Di Pasquale P; Castello A; Mauri F
    Ital Heart J Suppl; 2000 Jan; 1(1):81-7. PubMed ID: 10832123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased creatine kinase MB level predicts postoperative mortality after cardiac surgery independent of new Q waves.
    Ramsay J; Shernan S; Fitch J; Finnegan P; Todaro T; Filloon T; Nussmeier NA
    J Thorac Cardiovasc Surg; 2005 Feb; 129(2):300-6. PubMed ID: 15678039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pexelizumab: a novel therapy for myocardial ischemia-reperfusion.
    Patel MR; Granger CB
    Drugs Today (Barc); 2005 Mar; 41(3):165-70. PubMed ID: 15883613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials.
    Kitakaze M; Asakura M; Kim J; Shintani Y; Asanuma H; Hamasaki T; Seguchi O; Myoishi M; Minamino T; Ohara T; Nagai Y; Nanto S; Watanabe K; Fukuzawa S; Hirayama A; Nakamura N; Kimura K; Fujii K; Ishihara M; Saito Y; Tomoike H; Kitamura S;
    Lancet; 2007 Oct; 370(9597):1483-93. PubMed ID: 17964349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials.
    Smith PK; Shernan SK; Chen JC; Carrier M; Verrier ED; Adams PX; Todaro TG; Muhlbaier LH; Levy JH;
    J Thorac Cardiovasc Surg; 2011 Jul; 142(1):89-98. PubMed ID: 20880552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial.
    Berger JS; Roe MT; Gibson CM; Kilaru R; Green CL; Melton L; Blankenship JD; Metzger DC; Granger CB; Gretler DD; Grines CL; Huber K; Zeymer U; Buszman P; Harrington RA; Armstrong PW
    Am Heart J; 2009 Dec; 158(6):998-1004.e1. PubMed ID: 19958867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
    ; Bates E; Bode C; Costa M; Gibson CM; Granger C; Green C; Grimes K; Harrington R; Huber K; Kleiman N; Mochly-Rosen D; Roe M; Sadowski Z; Solomon S; Widimsky P
    Circulation; 2008 Feb; 117(7):886-96. PubMed ID: 18250271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study.
    Baran KW; Nguyen M; McKendall GR; Lambrew CT; Dykstra G; Palmeri ST; Gibbons RJ; Borzak S; Sobel BE; Gourlay SG; Rundle AC; Gibson CM; Barron HV;
    Circulation; 2001 Dec; 104(23):2778-83. PubMed ID: 11733394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of a routine early invasive strategy in relation to time from symptom onset to fibrinolysis (a subgroup analysis of TRANSFER-AMI).
    Russo JJ; Goodman SG; Cantor WJ; Tan MK; Borgundvaag B; Fitchett D; Džavík V; Yan RT; Graham JJ; Mehta SR; Yan AT;
    Am J Cardiol; 2015 Apr; 115(8):1005-12. PubMed ID: 25711435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction.
    Pride YB; Appelbaum E; Lord EE; Sloan S; Cannon CP; Sabatine MS; Gibson CM;
    Am J Cardiol; 2009 Aug; 104(4):475-9. PubMed ID: 19660597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial.
    Hudson MP; Armstrong PW; O'Neil WW; Stebbins AL; Weaver WD; Widimsky P; Aylward PE; Ruzyllo W; Holmes D; Mahaffey KW; Granger CB
    Circ Cardiovasc Qual Outcomes; 2011 Mar; 4(2):183-92. PubMed ID: 21304097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.